close

Enter

Log in using OpenID

Immuno-Oncology Drugs Market

embed
Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells.
Immuno-Oncology Drugs Market Trends And
Growth By 2025
Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by
stimulating the immune system instead of fighting the tumors, avoiding disturbance in
functionality of healthy cells. It helps the immune system to recognize and target cancer cells.
The therapy facilitates long term response against cancer by providing long-lasting memory to
the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which
include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma,
breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies
such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy,
cancer vaccines, and other therapies. Depending on the functioning of these therapies they are
further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and
bispecific monoclonal antibodies. Commercially available immune-oncology therapies include
Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1271
Introduction of novel immune-oncology therapies with lesser side effects is driving growth of
the global immune-oncology drugs market
Improved therapeutic outcomes have led to increasing success rates against cancer, owing to indepth understanding of the disease pathophysiology, functioning of the tumor cells, and
effective ways to tackle with the same. Moreover, immuno-oncology therapies have lesser side
effects compared to conventional cancer therapies such as chemotherapy, radiation therapy, and
others. Immuno-oncology therapy operates through the immune system of the body and does
not harm healthy cells as opposed to conventional therapies such as targeted therapy,
chemotherapy, and radiation therapy that affect cancerous as well as healthy cells. Novel
immune therapies can restore the ability of the immune system to identify and eliminate cancer
cells, which is generally suppressed during course of cancer progression. Such immuno-oncology
based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a,
human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is
available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed
death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab,
Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies
have been further developed into conjugated monoclonal antibodies, which are combined with
other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines
have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either
work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new
therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah
and Yescarta are available.
The global immuno-oncology drugs market was valued at US$ 43,084.5 million in 2016 and is
expected to witness a robust CAGR of 14.9% over the forecast period (2017 – 2025).
Report includes chapters which deeply display the following deliverable about industry :
• Immuno-Oncology Drugs Market Research Objective and Assumption
• Immuno-Oncology Drugs Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Immuno-Oncology Drugs Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Immuno-Oncology Drugs Market, By Regions
• Immuno-Oncology Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Immuno-Oncology Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Immuno-Oncology Drugs Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Immuno-Oncology Drugs Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Active research and development by leading players as well as small innovative organizations
are expected to boost growth of the immune-oncology drugs market
According to the World Health Organization (WHO), cancer was responsible for 8.8 million
deaths in 2015. Owing to benefits associated with these therapies, the leading players are
actively investing in research and development into this treatment category through various
collaborations and individual research studies. For instance, EMD Serono is involved in research
and development of immune-oncology drugs and has a few drugs in pipeline such as M7824
(investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug
manufacturer and MD Anderson Cancer Center entered into a strategic clinical research
collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx
announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing
immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver
cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immuneoncology research and the company launched an immunotherapy collaboration with Kite Pharma
to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1271
Some major players operating in the immuno-oncology drugs market include Amgen, Inc.
AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck &
Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc.,
Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics &
Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics,
ImmunoCellular Therapeutics, and Incyte.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge335   documents Email
Document
Category
Health and Medicine
Views
2
File Size
123 KB
Tags
oncology, Immuno-Oncology Drugs Market
1/--pages
Report inappropriate content